VICTORIA, British Columbia--(BUSINESS WIRE)--GenoLogics today announced that GenomeDx Biosciences has implemented GenoLogics’ laboratory information management system, Clarity LIMS, to support whole transcriptome analysis workflows as part of their mission to address unmet clinical needs in the management of prostate cancer. Headquartered in Vancouver, B.C., GenomeDx will use Clarity LIMS in its CLIA-certified lab in San Diego, CA.
In the U.S. alone, there are an estimated 2.5 million men who are living with prostate cancer. An estimated 230,000 are diagnosed each year with over 100,000 undergoing surgery to treat their cancer. According to clinical risk assessment, nearly half of men should be considered for post-surgery radiation even though their cancer may not recur. Using their groundbreaking genomic test, the Decipher® Prostate Cancer Classifier, GenomeDx is able to predict the probability of cancer spread for men after surgery. Clinicians can then use this information, along with other clinical factors, to better guide postoperative treatment decisions and in certain men, avoid the side effects and high costs associated with treatment.
Help employers find you! Check out all the jobs and post your resume